-
www.ahrq.gov/sites/default/files/wysiwyg/teamstepps/instructor/onlinecourse/tsonlinemodule3.pptx
December 01, 2005 - Needs to be clear information-- when uncertainty exist, it is your responsibility to clear up all ambiguity
-
www.ahrq.gov/sites/default/files/wysiwyg/teamstepps/instructor/onlinecourse/tsonlinemodule5.pptx
February 06, 2006 - A loss of situation awareness results in ambiguity, confusion, and a decrease in communication.
-
effectivehealthcare.ahrq.gov/products/renal-function/research-protocol
June 13, 2013 - If there is ambiguity in the cutoff used for the troponin assay, we will attempt to contact the manufacturer
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-function_research-protocol.pdf
June 13, 2013 - If there is ambiguity in the cut-off used for the
Source: www.effectivehealthcare.ahrq.gov
Published
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/renal-function_research-protocol.pdf
June 13, 2013 - If there is ambiguity in the cut-off used for the
Source: www.effectivehealthcare.ahrq.gov
Published
-
effectivehealthcare-admin.ahrq.gov/products/methods-guidance-de-novo-processes/methods
December 01, 2019 - Ambiguity about how to compare multiple existing SRs on the same subject remains an important challenge
-
hcup-us.ahrq.gov/datainnovations/clinicalcontentenhancementtoolkit/hi6.jsp
July 07, 2016 - SNM|
It is strongly recommended that the data types CE and SN be used whenever possible to minimize ambiguity
-
www.ahrq.gov/policymakers/chipra/demoeval/what-we-learned/final-report/section2.html
October 01, 2015 - because practice staff were not aware of their own EHRs functionalities and in some cases because of ambiguity
-
digital.ahrq.gov/sites/default/files/docs/citation/r01hs022087-singh-final-report-2018.pdf
January 01, 2018 - conventions for naming orders in the EHR improved the ability to
choose the intended order by reducing ambiguity
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/medication-reconciliation/chipra-173-fullreport.pdf
November 07, 2010 - in a combination of
yes/no boxes, checklists, and “Likert-type” formats to provide clarity, avoid ambiguity
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/medication-reconciliation/chipra-179-fullreport.pdf
November 07, 2010 - in a combination of
yes/no boxes, checklists, and “Likert-type” formats to provide clarity, avoid ambiguity
-
effectivehealthcare.ahrq.gov/sites/default/files/assessing-the-risk-of-bias_draft-report.pdf
June 02, 2011 - phrase ―risk of bias‖ instead of ―quality‖,
reasoning that ―an emphasis on risk of bias overcomes ambiguity
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/assessing-the-risk-of-bias_draft-report.pdf
June 02, 2011 - phrase ―risk of bias‖ instead of ―quality‖,
reasoning that ―an emphasis on risk of bias overcomes ambiguity
-
meps.ahrq.gov/data_files/publications/workingpapers/wp_19002.pdf
July 20, 2017 - SBD nodes and OBD data is ambiguous, the nodes are fielded during SBD data
collection to clear up ambiguity
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-149-fullreport.pdf
February 01, 2019 - Metabolic Screening for Children and Adolescents Newly on Antipsychotics
1
Metabolic Screening for Children and Adolescents
Newly on Antipsychotics
Section 1. Basic Measure Information
1.A. Measure Name
Metabolic Screening for Children and Adolescents Newly on Antipsychotics
1.B. Measure Number
0149
1.C. Me…
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-fullreport.pdf
February 14, 2018 - Metabolic Monitoring for Children and Adolescents on Antipsychotics
1
Metabolic Monitoring for Children and Adolescents
on Antipsychotics
Section 1. Basic Measure Information
1.A. Measure Name
Metabolic Monitoring for Children and Adolescents on Antipsychotics
1.B. Measure Number
0150
1.C. Measure Descripti…
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-fullreport.pdf
February 14, 2018 - Metabolic Monitoring for Children and Adolescents on Antipsychotics
1
Metabolic Monitoring for Children and Adolescents
on Antipsychotics
Section 1. Basic Measure Information
1.A. Measure Name
Metabolic Monitoring for Children and Adolescents on Antipsychotics
1.B. Measure Number
0150
1.C. Measure Descripti…
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-fullreport.pdf
February 14, 2018 - Metabolic Monitoring for Children and Adolescents on Antipsychotics
1
Metabolic Monitoring for Children and Adolescents
on Antipsychotics
Section 1. Basic Measure Information
1.A. Measure Name
Metabolic Monitoring for Children and Adolescents on Antipsychotics
1.B. Measure Number
0150
1.C. Measure Descripti…
-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-fullreport.pdf
February 14, 2018 - Metabolic Monitoring for Children and Adolescents on Antipsychotics
1
Metabolic Monitoring for Children and Adolescents
on Antipsychotics
Section 1. Basic Measure Information
1.A. Measure Name
Metabolic Monitoring for Children and Adolescents on Antipsychotics
1.B. Measure Number
0150
1.C. Measure Descripti…
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-fullreport.pdf
February 14, 2018 - Metabolic Monitoring for Children and Adolescents on Antipsychotics
1
Metabolic Monitoring for Children and Adolescents
on Antipsychotics
Section 1. Basic Measure Information
1.A. Measure Name
Metabolic Monitoring for Children and Adolescents on Antipsychotics
1.B. Measure Number
0150
1.C. Measure Descripti…